A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies

A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies

10.1177/17588359221087555

Saved in:
Bibliographic Details
Main Authors: Ho, Jingshan, Heong, Valerie, Yong, Wei Peng, Soo, Ross, Chee, Cheng Ean, Wong, Andrea, Sundar, Raghav, Thian, Yee Liang, Gopinathan, Anil, Pang, Mei Yan, Koe, Priscillia, Jeraj, Santhiay Nathan, Soe, Phyu Pyar, Soe, Mu Yar, Tang, Tiffany, Ng, Matthew CH, Tai, David WM, Tan, Tira JY, Xu, Hongmei, Chang, Hua, Landesman, Yosef, Shah, Jatin, Shacham, Sharon, Lee, Soo Chin, Tan, Daniel SW, Goh, Boon Cher, Tan, David SP
Other Authors: CANCER SCIENCE INSTITUTE OF SINGAPORE
Format: Article
Language:English
Published: SAGE PUBLICATIONS LTD 2022
Subjects:
Science & Technology
Life Sciences & Biomedicine
Oncology
advanced malignancies
Asian
clinical trial
phase 1
selinexor
ANTITUMOR-ACTIVITY
DEXAMETHASONE
1ST-IN-CLASS
CONSENSUS
LYMPHOMA
CRITERIA
Online Access:https://scholarbank.nus.edu.sg/handle/10635/226297
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: National University of Singapore
Language: English

Internet

https://scholarbank.nus.edu.sg/handle/10635/226297

Similar Items